My Portfolio
+
LINK YOUR PORTFOLIO

Dyne Therapeutics, Inc DYN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 06/02/26 EDT
17.99quote price arrow up+0.75 (+4.35%)
Volume
1,514,385
52 week range
8.06 - 25.00
Loading...
  • Open17.25
  • Day High18.07
  • Day Low17.19
  • Prev Close17.99
  • 52 Week High25.00
  • 52 Week High Date10/28/25
  • 52 Week Low8.06
  • 52 Week Low Date07/07/25

Latest On Dyne Therapeutics, Inc

Key Stats

  • Market Cap2.974B
  • Shares Out165.31M
  • 10 Day Average Volume1.57M
  • Dividend-
  • Dividend Yield-
  • Beta1.09

Latest On Dyne Therapeutics, Inc

KEY STATS

  • Open17.25
  • Day High18.07
  • Day Low17.19
  • Prev Close17.99
  • 52 Week High25.00
  • 52 Week High Date10/28/25
  • 52 Week Low8.06
  • 52 Week Low Date07/07/25
  • Market Cap2.974B
  • Shares Out165.31M
  • 10 Day Average Volume1.57M
  • Dividend-
  • Dividend Yield-
  • Beta1.09

RATIOS/PROFITABILITY

  • EPS (TTM)-3.22
  • P/E (TTM)-5.58
  • Fwd P/E (NTM)-5.91
  • EBITDA (TTM)-468.941M
  • ROE (TTM)-58.89%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)17.99%

EVENTS

  • Earnings Date07/27/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and...
Jason Rhodes
Independent Chairman of the Board
John Cox
President, Chief Executive Officer, Director
Erick Lucera
Chief Financial Officer, Treasurer
Address
1560 Trapelo Road
Waltham, MA
02451
United States